AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$1.68 USD
+0.04 (2.44%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.80 +0.12 (7.14%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AEON 1.68 +0.04(2.44%)
Will AEON be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AEON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AEON
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
Other News for AEON
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450’s Broad Market Potential
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
Aeon Biopharma discontinues Phase 2 study of ABP-450 in chronic migraine
Aeon announces strategic resource reprioritization, cuts workforce by 55%
12 Health Care Stocks Moving In Thursday's Pre-Market Session